MedPath

PRobiotics for EVEry Newborn Trial

Not Applicable
Completed
Conditions
Colic
Infantile
Interventions
Dietary Supplement: L. reuteri
Registration Number
NCT04537494
Lead Sponsor
The Hospital for Sick Children
Brief Summary

The aim of the study is to compare prevention (oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks) with treatment-as-needed (supplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age). This is a single site pilot study to assess feasibility for a full trial.

Detailed Description

One in five infants experience colic, defined as recurrent and prolonged episodes of crying and fussing with no obvious cause in healthy infants less than 5 months of age. There is evidence to support the role of the probiotic L. reuteri for treatment of colic in breastfed babies and for prevention of colic. However, these two options (prevention vs treatment-as-needed) have not been previously compared head-to-head. The study aims determine if oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks (prevention) is superior to treatment-as-needed, as measured by daily cry/fuss duration at 6 and 12 weeks of age.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria
  1. 1 to 7 days of age
  2. term (37 to 41 weeks)
  3. breast or formula fed
  4. birth weight > 2500 grams
  5. parental consent
Exclusion Criteria
  1. congenital or other medical disorders
  2. parents unable to communicate in English or French

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatment-as-neededL. reuteriSupplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age
PreventionL. reuteriOral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks
Primary Outcome Measures
NameTimeMethod
Combined infant daily cry/fuss duration12 weeks

The primary outcome will be infant daily cry/fuss duration (combined cry and fuss in minutes) measured using the modified Baby's Day Diary over a 48 hour period.

Secondary Outcome Measures
NameTimeMethod
Infant daily fuss duration6 weeks

Daily fuss duration will be examined separately

Gut microbial composition, diversity and function12 weeks

Microbial composition, diversity and function will be measured in infant fecal samples.

Infant colic12 weeks

Daily cry/fuss of at least 180 minutes

Infant daily cry duration12 weeks

Daily cry duration will be examined separately

Parent (female and male) fatigue12 weeks

Fatigue will be measured using a validated Fatigue Visual Analogue Scale. Scores will range between 0 and 180, higher score means worse outcome

Adverse effects - growth/length16 weeks

Infant growth (length) will be measured at scheduled health supervision visits

Adverse effects - growth/head circumference16 weeks

Infant growth (head circumference) will be measured at scheduled health supervision visits

Health services utilization12 weeks

Frequency of assessments

Infant daily sleep duration12 weeks

Sleep duration will be measured objectively using actigraphy worn around the infant's ankle over a sock.

Parent (female and male) mental health12 weeks

Mental health will be measured using the Edinburgh Postnatal Depression Scale, a validated 10-item screening questionnaire. Scoring is between o and 30 and higher score means worse outcome.

Adverse effects - digestive upset16 weeks

Number of participants with occurrences of digestive upset (e.g., diarrhea), in the Baby's Day Diary

Adverse effects - growth/weight16 weeks

Infant growth (weight) will be measured at scheduled health supervision visits

Trial Locations

Locations (1)

The Hospital for Sick Children

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath